Stockreport

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals [Yahoo! Finance]

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com
PDF Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of progeria, a collection of ultra-rare, fatal, gene [Read more]